ZN-d5
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, Non Hodgkin Lymphoma
Trial Timeline
Oct 13, 2020 → Dec 12, 2023
NCT ID
NCT04500587About ZN-d5
ZN-d5 is a phase 1 stage product being developed by Zentalis Pharmaceuticals for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04500587. Target conditions include Acute Myeloid Leukemia, Non Hodgkin Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05199337 | Phase 1/2 | Completed |
| NCT04854174 | Phase 1 | Completed |
| NCT04500587 | Phase 1 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia